Zynerba Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ZYNE Zynerba Pharmaceuticals Inc
FFC Flaherty & Crumrine Preferred Securities Income Fund
KGJI Kingold Jewelry Inc
PARA Paramount Global
TFINP Triumph Financial Inc
HWKN Hawkins Inc
COUP Coupa Software Inc
ACAZF Acadian Timber Corp
BSX Boston Scientific Corp
ACDVF Air Canada
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome (FXS), autism spectrum disorder (ASD), and 22q11.2 deletion syndrome (22q). Cannabinoids are a class of compounds derived from Cannabis plants. Its two primary cannabinoids contained in cannabis are cannabidiol and tetrahydrocannabinol (THC). The Company is developing Zygel, the pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of THC. Zygel is being developed as a clear gel with once- or twice-daily dosing and is targeting the treatment of behavioral symptoms of FXS, ASD and 22q. It has evaluated Zygel targeting the reduction of seizures in patients with a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).

Price
Delayed
$0.605
Day's Change
-0.0295 (-4.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.63
Day's Low
0.5815
Volume
(Below Average)

Today's volume of 38,163 shares is on pace to be lower than ZYNE's 10-day average volume of 266,169 shares.

38,163

Display:

Providers:

UpdateCancel
6 providers
January 11, 2023
December 21, 2022
December 05, 2022
November 29, 2022
November 28, 2022
November 15, 2022
November 14, 2022
November 02, 2022

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.